Ibrance and Vancomycin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ibrance (palbociclib) and Vancomycin (vancomycin). Common drug interactions include asthenia among females.

The phase IV clinical study analyzes what interactions people have when they take Ibrance and Vancomycin. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Ibrance?

Ibrance has active ingredients of palbociclib. eHealthMe is studying from 104,434 Ibrance users. Check the latest studies of Ibrance.

What is Vancomycin?

Vancomycin has active ingredients of vancomycin. eHealthMe is studying from 17,165 Vancomycin users. Check the latest studies of Vancomycin.



On Jul, 12, 2026

12 people who take Ibrance and Vancomycin together, and have interactions are studied.

Ibrance and Vancomycin drug interactions.

What are the common drug interactions of Ibrance and Vancomycin, by gender? *:

female:

  1. Asthenia (weakness)
  2. Myalgia (muscle pain)
  3. Diarrhoea
  4. Nausea (feeling of having an urge to vomit)
  5. Pain
  6. Spinal cord compression
  7. Chest pain
  8. Cystitis (inflammation of the wall of the bladder)
  9. Dysuria (painful or difficult urination)
  10. Granulocyte count increased

male:

n/a

What are the common drug interactions of Ibrance and Vancomycin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Anaemia (lack of blood)
  2. Bone marrow disorder
  3. Clostridium difficile colitis (inflammation of colon by clostridium difficile bacteria infection)
  4. Constipation
  5. Decreased appetite
  6. Diarrhoea
  7. Nausea (feeling of having an urge to vomit)
  8. Pain
  9. Spinal cord compression
  10. White blood cell count decreased

60+:

  1. Asthenia (weakness)
  2. Myalgia (muscle pain)
  3. Haemoglobin decreased
  4. Lethargy (tiredness)
  5. Mean cell volume increased (more than normal average red blood cell volume)
  6. Platelet count decreased
  7. Pyrexia (fever)
  8. Sepsis (a severe blood infection that can lead to organ failure and death)
  9. Tachycardia (a heart rate that exceeds the range of 100 beats/min)
  10. Death

What are the existing conditions these people have? *

  1. Breast Cancer: 3 people, 25.00%
  2. Breast Cancer Female: 3 people, 25.00%
  3. Breast Cancer Metastatic: 3 people, 25.00%
  4. Metastases To Bone (cancer spreads to bone): 2 people, 16.67%
  5. Diarrhea: 2 people, 16.67%
  6. Urinary Tract Infection: 1 person, 8.33%
  7. Eye Swelling: 1 person, 8.33%
  8. Agitation (state of anxiety or nervous excitement): 1 person, 8.33%
  9. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 8.33%
  10. Breast Cancer Recurrent: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Ibrance and Vancomycin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Ibrance and Vancomycin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ibrance:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Vancomycin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ibrance and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Vancomycin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on palbociclib and vancomycin (the active ingredients of Ibrance and Vancomycin, respectively), and Ibrance and Vancomycin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: